31 articles - From Friday Dec 09 2022 to Friday Dec 16 2022
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Oncol |
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. With approximately 5 years of follow-up, pembrolizumab monotherapy continued to demonstrate durable efficacy with no new safety signals in patients with platinum-resistant metastatic UC and as first-line therapy in cisplatin-ineligible patients. Clinical trial registry and ID ClinicalTrials.gov, NCT02256436 (KEYNOTE-045) and NCT02335424 (KEYNOTE-052). |
Identification, validation and biological characterization of novel Glioblastoma Tumour Microenvironment subtypes: Implications for precision immunotherapy. We have established a novel TME-based classification system for application in intracranial malignancies. TME-subtypes represent canonical "termini a quo" (starting points) to support an improved precision immunotherapy treatment approach. |
| Blood |
Cloned antibodies from patients with heparin-induced thrombocytopenia (HIT) provide new clues to HIT pathogenesis. Repertoire sequencing showed that the frequency of peripheral blood IgG+ B cells possessing RKH or Y5 was significantly higher in HIT than in non-HIT patients given heparin, indicating expansion of B cells possessing RKH or Y5 in HIT. These findings imply that antibodies possessing RKH or Y5 are relevant to HIT pathogenesis and suggest new approaches to diagnosis and treatment of this condition. |
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy. The mutational burden was similar throughout differentiation, with even the most mutated stem and progenitor clones maintained their capacity to differentiate to mature cell types in vivo. Increased contributions from productive mutant progenitors appear to underlie improved hematopoiesis in MDS following HMA therapy. |
HLA-E-Restricted Immune Responses Are Crucial for the Control of EBV Infections and the Prevention of PTLD. The further progression to EBV+PTLD was highly associated with the presence of both peptide-encoding EBV-strains and the expression of HLA-E*0103/0103 in the host. Thus, HLA-E-restricted immune responses and the NKG2A/LMP-1/HLA-E axis are novel predictive markers for EBV+PTLD in transplant recipients and should be considered for future EBV vaccine design. |
How I Prevent Viral Reactivation in High-risk Patients. Fewer data are available on the effective prevention of human herpesvirus 6 (HHV-6), Epstein-Barr virus (EBV), Adenovirus (ADV) and BK virus infections. To highlight the spectrum of clinical practice, here we review high-risk situations that we handle with a high degree of uniformity, and cases that feature differences in approaches, reflecting distinct HCT practices such as ex-vivo T cell depletion. |
RUNX1 isoform disequilibrium promotes the development of trisomy 21 associated myeloid leukemia. Moreover, pharmacological interference with MYC:MAX dimerization using MYCi361 exerted strong anti-leukemic effects. Thus, our study highlights the importance of alternative splicing in leukemogenesis, even on a background of aneuploidy, and paves the way for the development of specific and targeted therapies for ML-DS, as well as for other leukemias with Hsa21 aneuploidy or RUNX1 isoform disequilibrium. |
The Histone Methyltransferase MLL1/KMT2A in Monocytes Drives Coronavirus-Associated Coagulopathy and Inflammation. We also observed elevated plasma urokinase and TF activity in COVID-positive samples. Collectively, these findings highlight an important role for MO/Mf MLL1 in promoting coronavirus-associated coagulopathy and inflammation. |
| Blood Adv |
An NFIX-mediated regulatory network governs the balance of hematopoietic stem and progenitor cells during hematopoiesis. Additionally, we provide evidence suggesting the absence of NFIX negatively affects PU.1 binding at some genomic loci. Our data support a model in which NFIX collaborates with PU.1 at super-enhancers to promote the differentiation and homeostatic balance of hematopoietic progenitors. |
Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept. The results of both the transfusion experiments and the atomic force spectroscopy suggest mechanically stimulated protein transfer to red blood cells as a protein source in the absence of the translational machinery. This protein transfer mechanism has the potential to be utilized in therapeutic contexts, especially for hereditary diseases involving red blood cells, such as hereditary xerocytosis or Gárdos channelopathy. |
Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice. Under these conditions, transfused platelets were still circulating after 24 h, whereas they were rapidly removed from the circulation of alloimmunized mice. The identification of MZB cells as key players in the platelet alloimmune response opens up new perspectives to minimize platelet alloimmunization and avoid the associated refractory state in frequently transfused patients. |
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best option of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients. |
Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII. Finally, overexpression of both LMAN1 and MCFD2 does not further increase FV/FVIII secretion, suggesting that the amount of the LMAN1-MCFD2 receptor complex is not a rate-limiting factor in ER-Golgi transport of FV/FVIII. This study provides new insight into the molecular mechanism of F5F8D and the intracellular trafficking of FV and FVIII. |
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARa Agonist, is a Novel Approach in AML. These results support further evaluation of tamibarotene-based treatment strategies in AML and MDS patients with RARA overexpression to provide a targeted approach with the goal of improving patient outcomes. This trial is registered at as NCT02807558. |
| J Hematol Oncol |
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. These data, representing the longest follow-up of CAR T-cell therapy in a multicenter study of adult R/R B-ALL, suggest that KTE-X19 provides a clinically meaningful survival benefit with manageable toxicity in this population. |
| Thromb Haemost |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Blood |
| CA Cancer J Clin |
Interventional gastroenterology in oncology. With advancements in technology and endoscopic techniques, endoscopy has become the core in diagnosis and management of gastrointestinal tract cancers. In this extensive review, the authors discuss the role endoscopy plays in early detection, diagnosis, and management of esophageal, gastric, colorectal, pancreatic, ampullary, biliary tract, and small intestinal cancers. |
| J Hematol Oncol |
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments. |
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. The etiology of triggering osimertinib resistance is complex including EGFR-dependent and EGFR-independent pathways, and different therapeutic strategies for the NSCLC patients with osimertinib resistance have been developed. Herein, we comprehensively summarized the resistance mechanisms of osimertinib and discuss in detail the potential therapeutic strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine. |
| Lancet Haematol |
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Splanchnic vein thrombosis is not an absolute contraindication for HCT, but a multidisciplinary approach is warranted. Finally, prevention and treatment of COVID-19 should adhere to standard recommendations for immunocompromised patients. |
| Leukemia |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Blood |
| Leukemia |
Letters to the editors and authors’ replies